CytRx Corp. announced Wednesday that it has begun patientenrollment in a new clinical trial on RheothRx Injection inpatients with suspected heart attack.
The 250-patient study is being conducted by BurroughsWellcome Co. of Research Triangle Park, N.C., which licensed thecompound from CytRx (NASDAQ:CYTR) of Norcross, Ga., in 1990.
Two other studies on ReothRx Injection in heart attack patientshave been in progress since March 1992 and are now nearingcompletion, the company said.
(c) 1997 American Health Consultants. All rights reserved.